Thus Sarm1 deletion or inhibition may effectively reduce RGC loss in glaucoma and, given the scarcity of treatments for glaucoma, the potential of Sarm1 as a therapeutic target is intriguing. This evidence concerns the gene SARM1 and glaucoma.